Podcasts about phase ii

What if the most talked-about healing peptide in biohacking came from your own stomach — and carried a risk nobody in the space is talking about?BPC-157, nicknamed "the Wolverine Peptide," has taken over fitness forums, longevity podcasts, and regenerative medicine circles. The preclinical data on tissue repair is remarkable. But the same biological mechanism that drives its healing power is the exact mechanism tumors use to survive and grow.BPC-157 is a synthetic 15 amino acid sequence isolated from human gastric juice, first identified in the early 1990s. It drives tissue repair through six mechanisms: angiogenesis via VEGF upregulation, nitric oxide pathway modulation, FAK paxillin signaling activation, growth hormone receptor upregulation in tendons and ligaments, anti-inflammatory cytokine downregulation, and free radical scavenging for cell protection. An active Phase II randomized controlled trial is currently evaluating BPC-157 for acute hamstring muscle strain repair. Its pro-angiogenic properties raise a theoretical cancer risk in individuals with undiagnosed early-stage tumors. WADA has banned it for competitive athletes. The FDA has reclassified its availability and the FDA Pharmacy Compounding Advisory Committee is reviewing its status on the approved bulk substances list.Dr. Joy Kong talks about:00:00 Meet The Wolverine Peptide02:40 Discovered Inside Human Gastric Juice03:42 Six Pathways That Drive Healing07:33 The First Real Human Trial07:58 Why The FDA Cracked Down09:24 The Hidden Cancer RiskAdditional Resources:✨ Visit My Clinic: Chara Health

On the KMOJ Morning Show, Malik Rucker, founding Executive Director of V3 Sports, joined Freddie Bell for the "Community Builders Series" to discuss his North Minneapolis roots and the experiences that inspired his mission to invest in the community through health, wellness, and opportunity. A fifth-generation Northsider, Rucker reflected on the vision behind V3 Sports and how the organization has grown from a one-person operation into a major nonprofit serving families through fitness, aquatics, youth programming, and education. He explained that V3's mission extends far beyond athletics, focusing on building healthier communities, creating access, and strengthening economic empowerment through intentional partnerships with Northside businesses. Rucker also shared the pride he feels seeing the completed first phase of the V3 Center in action and looked ahead to Phase II, which will bring an Olympic-sized pool and expanded programming to further serve the community. 

We’re starting our read of Tales of Light and Life, a collection of short stories by the authors of the High Republic project. Join us as we discuss transitioning from Phase II to Phase III, Marda Ro sowing the seeds of the Nihil, and the aftermath of the fall of Starlight Beacon. For a list […]

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Power Metallic Mines Inc. (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1)Power Metallic is expanding its summer 2026 exploration program at the Nisk Project in Quebec with three advanced geophysical surveys — SQUIDs, gravity, and Ambient Noise Tomography — designed to pinpoint deeper Ni-Cu-PGE mineralization. These surveys run alongside a 30,000-metre diamond drill program already being mobilized for Q2 and Q3 2026. Investors in the critical metals space should take note as the company systematically targets extensions to the high-grade Lion Zone and new discoveries across the enlarged land package.Minaurum Silver Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M0)Minaurum has reported high-grade drill results from the Europa Sur Vein Zone at the Alamos Silver Project in Sonora, Mexico, highlighted by 3.20 metres of 882 g/t silver equivalent including a peak of 2,423 g/t AgEq over 0.95 metres. Elevated gold and copper values suggest the presence of a high-temperature feeder structure, substantially boosting resource expansion potential within the ongoing 50,000-metre Phase II drill program. Alamos already hosts a 55.4 Moz AgEq inferred resource.Sitka Gold Corp. (TSXV: SIG) (FSE: 1RF) (OTCQX: SITKF)Sitka Gold's first 2026 drill hole at the Blackjack deposit returned 94.0 metres of 1.79 g/t gold including 19.3 metres of 5.04 g/t gold from 1,093 metres depth — the deepest hole ever completed at the RC Gold Project in Yukon. The result extends high-grade gold approximately 370 metres below the existing resource pit and confirms strong continuity with last year's deep discovery. With four rigs active on a fully funded 60,000-metre program, the company is rapidly advancing a district-scale gold system hosting over 5.1 million ounces across indicated and inferred resources.CopAur Minerals Inc. (TSXV: CPAU)CopAur released a Preliminary Economic Assessment and a 52% increase in Mineral Resource Estimate for its Kinsley Mountain Gold Project in Nevada, now totaling 742,000 indicated ounces at 1.11 g/t gold. At the current spot gold price of US$4,500/oz, the project delivers a post-tax NPV of US$147 million and an IRR of 66% with a 1.5-year payback on pre-production CAPEX of US$81.8 million. For a small-cap company with a modest market capitalization, owning 100% of a permitted Nevada heap-leach gold project with these economics represents a potentially significant value proposition.Bottom Line: Today's stories highlight a sector in full motion — high-grade silver and gold drilling campaigns advancing in Mexico and the Yukon, paired with a Nevada gold project delivering compelling PEA economics. Critical metals exploration and near-term gold production potential are the dominant themes.Stay ahead of the market — follow AGORACOM for more breaking small-cap news and insights.

Vikings 2026 Expectations: Rookie Roles, Kyler Murray Fit, and Key Free-Agent Additions — Tyler Forness and Dave Stefano discuss realistic 2026 expectations for the new Minnesota Vikings, focusing on rookies, select UDFAs, and veteran additions. First-round DT Caleb Banks is framed as a long-term play, with year-one goals of staying relatively healthy, playing roughly 500–550 snaps, generating steady pressure, and building consistency. Second-round LB Jake Golday is projected primarily as an off-ball coverage linebacker used in sub-packages while he develops processing and run-fit skills, with caution against labeling him the next Andrew Van Ginkel. They outline modest roles for other picks (including Domonique Orange as a solid nose tackle, limited expectations for Caleb Tiernan and Jakobe Thomas, special-teams emphasis for Max Bredeson and Charles Demmings, skepticism about Demond Claiborne making the roster, and uncertain outlook for seventh-rounder Gavin Gerhardt) and note UDFAs to watch. Among veterans, Kyler Murray is expected to stay healthy and run Kevin O'Connell's offense with more consistency, while James Pierre, Jauan Jennings, and Isaiah Loudermilk are expected to be solid contributors. Timestamps: 00:00 Season Expectations Setup 00:14 Show Intro and Format 01:05 Why Expectations Matter 02:09 QB WR Workouts Note 02:33 Draft Class Kickoff 02:49 Caleb Banks Outlook 07:58 Jake Golday Role Debate 21:34 Domonique Orange Projection 23:34 Other Third Rounders 25:34 Jakobe Thomas and Safety Room 27:39 Harrison Smith Return Talk 30:04 Day Three Picks Begin 30:44 Fullback Role Unknown 31:48 Can Bredeson Win Job 33:05 No Friends Drafting 34:14 Demmings Development Plan 35:12 Claiborne Roster Doubts 40:44 Late Picks And UDFAs 41:49 Punter Battle And Cap 42:30 Kyler Murray Expectations 45:05 Fixing Explosives Vs Consistency 49:05 Free Agents Pierre Jennings 52:19 Loudermilk Camp Fit 53:49 Wrap Up And Schedule _______________________ ⭐️ Subscribe to us here! - https://www.youtube.com/@vikings1stskol92 ⭐️ Our Twitter can be found at @Vikings1stSKOL ⭐️ Our Discord at https://discord.com/invite/493z6mQXcN ⭐️ Tyler Forness can be read at A to Z Sports - https://atozsports.com/nfl/minnesota-vikings-news/ ⭐️ Submit questions: forms.gle/7LJkCAern9kdUkuD8 ⭐️ On Facebook - https://www.facebook.com/vikings1standskol ⭐️ Watch the live show here: https://youtu.be/-cl_KEGFuws Fan With Us!!! Tyler Forness @TheRealForno of Vikings 1st & SKOL @Vikings1stSKOL and A to Z Sports @AtoZSportsNFL, with Dave Stefano @Luft_Krigare producing this Vikings 1st & SKOL production, the @RealFornoShow. Podcasts partnered with Fans First Sports Network @FansFirstSN. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of BioTalk with Rich Bendis, Sam Gussman-Toh, Portfolio Manager for the Small Business Program at ARPA-H, joins the conversation to discuss how the agency is creating new pathways for small businesses developing ambitious health technologies. Sam explains how the ARPA-H model differs from traditional federal funding programs, with a focus on moonshot health solutions, program manager-led portfolios, milestone-driven contracts, and a strong emphasis on moving technologies toward real-world use. He also discusses how the Small Business Program supports SBIR and STTR performers through Phase I, Phase II, Direct to Phase II, and Fast Track awards. The conversation highlights how ARPA-H is working with ambitious small businesses, including non-traditional companies and early-stage startups that may be working with the federal government for the first time. Sam also shares how commercialization support is built into the program, including ARPA-H's Entrepreneur-in-Residence partnership with BioHealth Innovation. Through that relationship, BHI EIRs help performers strengthen regulatory strategy, intellectual property planning, go-to-market strategy, reimbursement considerations, and other key commercialization needs. Sam also discusses ARPA-H's draft Small Business Program solicitation, the upcoming virtual Proposers' Day on June 11, and what companies should know about the application process, topic areas, technical pitches, and future funding opportunities. Editing and post-production work for this episode was provided by The Podcast Consultant. Sam Gussman-Toh is Portfolio Manager for the Small Business Program at ARPA-H, where he coordinates and oversees the agency's SBIR/STTR awards and commercialization support services for participating small businesses. Sam joined ARPA-H in 2022 and wrote the agency's first SBIR/STTR solicitation. He has held several roles in the Office of Commercialization and has worked closely with Program Managers to build the agency's commercialization infrastructure and strategy. Previously, Sam designed and managed rapid prototyping programs across agencies in the Department of War. His technical background is in computer science, with interests in computer vision, autonomous robotic systems, and computational pathology.

Acute respiratory distress syndrome (ARDS) induced by COVID-19 was a leading cause of severe illness and death during the pandemic, driven by an intense innate immune response, hyperinflammation, and a decrease in lymphocytes. Mesenchymal stromal cells (MSCs) represent a potential therapeutic option for ARDS due to their ability to modulate the immune system and inflammation. Our guests report results from a Health Canada–regulated Phase I and Phase II trials evaluating freshly cultured umbilical cord–derived MSCs in patients with COVID-19-related ARDS, including assessments of safety, maximum feasible tolerated dose, and preliminary efficacy. Their work explores a therapeutic strategy to improve ARDS outcomes using MSCs, which will be important for optimizing and targeting future cellular therapies.GuestDuncan Stewart, MD, Ottawa Hospital Research Institute and University of Ottawa, CanadaElmira Safaie Qamsari, Ottawa Hospital Research Institute, CanadaHostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting DocumentsPaper link: Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials About Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. X: @StemCellReportsAbout ISSCRAcross more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to advancing stem cell research and its translation to medicine.ISSCR StaffKeith Alm, Shuangshuang Du, Kym Kilbourne, Megan Koch, Jack Mosher, and Hunter Reed

JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT

As cancer vaccines move into Phase II and III clinical trials, it isincreasingly important for surgeons to understand their role in thisevolving landscape. What exactly are these vaccines, how do they work,and what should the surgical community know about theirimplementation? Join BTK surgical education fellows Kara Button andMichelle LaBella as they sit down with Professor Robert Jones to breakdown the science of mRNA vaccines, the logistics of tissueprocurement, and the future of cancer care.Hosts:- Professor Robert Jones: Consultant Liver Surgeon, Liverpool UniversityHospitals; UK National Institute for Healthcare Research, Co-Lead forthe Cancer Vaccine Innovation Pathway, Bowel Cancer UK and RoyalCollege of Surgeons UK Lead for Research into Advanced Bowel Cancer,and UK Chief Investigator for the BNT122-01 trial.https://www.linkedin.com/in/robert-jones-6103722a/- Kara Button, DO: General Surgery Resident, Maine Medical Center;Behind the Knife Surgical Education Fellow.- Michelle LaBella, MD: General Surgery Resident; University of NorthCarolina; Behind the Knife Surgical Education Fellow.References:https://clinicaltrials.biontech.com/trials/BNT122-01Jones RP, Lee LYW, Corrie PG, et al. Individualized cancer vaccinesversus surveillance after adjuvant chemotherapy for surgicallyresected high-risk stage 2 and stage 3 colorectal cancer: protocol fora randomized trial. BJS. 2023;110(12):1883-1884.doi:10.1093/bjs/znad332https://pubmed.ncbi.nlm.nih.gov/37856683/Tie J, Wang Y, Loree JM, et al. Circulating tumor DNA-guided adjuvanttherapy in locally advanced colon cancer: the randomized phase 2/3DYNAMIC-III trial. Nat Med. 2025;31(12):4291-4300.doi:10.1038/s41591-025-04030-whttps://pubmed.ncbi.nlm.nih.gov/41115959/Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigenvaccines stimulate T cells in pancreatic cancer. Nature.2023;618(7963):144-150. doi:10.1038/s41586-023-06063-yhttps://pubmed.ncbi.nlm.nih.gov/37165196/https://www.cancer.ox.ac.uk/research/lynchvax#:~:text=The%20LynchVax%20program%2C%20funded%20by,individuals%20with%20this%20genetic%20conditionPlease visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

In this episode, Surani explores one of biotech's most controversial and ambitious frontiers: psychedelic medicine. At the center of the story is Compass Pathways, the London-based biotech attempting to bring synthetic psilocybin through the modern drug approval system for treatment-resistant depression. What began as a deeply personal mission for founders George and Katya Goldsmith has evolved into one of the most closely watched companies in mental health biotech, surviving both the psychedelic hype cycle and the broader biotech market crash. Surani speaks with CEO Kabir Nath to explore Compass's unusual financing journey, the rise of institutional interest from investors like Otsuka Pharmaceutical, and the company's pivotal Phase II and Phase III studies that may ultimately lead to the first FDA-approved psychedelic medicine. She is also joined by renowned neuropsychopharmacologist Professor David Nutt from Imperial College London to unpack the science, investor skepticism, regulatory concerns and implementation complexities surrounding psychedelics. Timestamps 00:01 — Introduction 02.00 — The Compass origin story: George and Katya Goldsmith, psilocybin, and building a biotech 07:00 — Early financing struggles, Peter Thiel, and why traditional biotech investors stayed away 08:30 — Otsuka, and the moment psychedelics entered the mainstream 11:00 — Compass IPOs into the biotech boom — then the market crashes 13:00 — The controversial Phase IIb results: remission rates, safety concerns, and investor backlash 21:00 — Kabir Nath joins Compass as CEO to launch the Phase III program 22:00 — Breaking down the Phase III data, durability questions, and FDA approval odds 26:00 — Lykos' FDA fiasco, psychotherapy, blinding debates, and the regulatory challenge for psychedelics 31:00 — Real-world rollout: J&Js Spravato, scalability, pricing, reimbursement, and Compass's future vision Founders' Story: Business Insider Article After On podcast: For any comments, questions or feedback you can connect directly with Surani Fernando on LinkedIn or email: raisingbiotech@gmail.com Title music composed by: Yrii Semchyshyn (Coma Media)

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson tells Proactive's Stephen Gunnion that 2025 was a transformational year, marked by the acquisition of Awakn Life Sciences, a strategic rebrand, and a sharp refocus on high-burden CNS disorders. The centrepiece of the conversation is lead programme SVN-001 and the decision to take it through phase III rather than pursue an early licensing deal. Tennyson is direct about the rationale: shareholder value is greater at the end of a successful phase III than before it. Phase II data for SVN-001 in severe alcohol use disorder showed meaningfully improved sobriety outcomes, and the broader pipeline — including SVN-002 and early-stage asset SVN-015 — continues to advance across addiction and psychiatry. Tennyson also flags improving conditions in the US, with growing regulatory and investor support providing a useful tailwind for the sector. For more insights and updates on emerging biotech companies, visit Proactive's YouTube channel, like this video, subscribe, and enable notifications so you never miss future content. #SolvonisTherapeutics #BiotechPipeline #CNSDisorders #DrugDevelopment #SVN001 #AlcoholUseDisorder #BiotechInvesting #PharmaInnovation #ClinicalTrials #HealthcareInnovation #AddictionTreatment #BiotechNews

João Canêdo of Fenix Gold, own and operated by Rio2, joins Trevor for an MSD interview following last week's site visit to the Fenix Gold Project. João provides a thorough update on the mine's construction, which is close to complete. The company has produced dore leading up to its full commissioning. But Fenix continues to think long-term with the strategy of a Phase II. He walks us through those ideas of how to truly optimize the mine plan.

Big Breaking! Opinion Poll Gives Clear Majority to BJP | 60/142 in Phase II, 154/294 Overall

Listen below or click here for full show notes Main Mission, Part 1 (with an appropriate sound effect) Starfleet Academy cancelled Star Trek: Starfleet Academy EP Confirms Season 2’s Major Risk ‘Star Trek: Starfleet Academy’ Canceled After Two Seasons Why Paramount Plus Ended Star Trek: Starfleet Academy After Two Seasons Star Trek: Starfleet Academy Ending With Season 2 Breaking — STAR TREK: STARFLEET ACADEMY Ends with Season 2, Wrapping Known Kurtzman-Era Productions – TrekCore.com ‘Star Trek: Starfleet Academy’ To End With Season 2 At Paramount+ ‘Star Trek: Starfleet Academy’ to End With Season 2 (EXCLUSIVE) William Shatner Speaks Out After Starfleet Academy’s Cancellation: ‘That Aspect Of Star Trek I’ve Always Loved’ William Shatner Breaks Silence on Surprise ‘Star Trek: Starfleet Academy’ Cancelation – Men’s Journal Paramount+ Is Dismantling Star Trek After a Historic 9-Year Streaming Run Star Trek is Adrift: Why ‘Starfleet Academy’ is Folding After Season 2 The Real Reason for Paramount Dismantling Star Trek’s 9-Year Streaming Run Isn’t What You Think David Ellison On Cost Savings, Growth, The Tech Stack & AI As WBD Merge Star Trek: Starfleet Academy Cancellation Explained By Robert Picardo These 7 Rumored ‘Star Trek’ Shows Could Save the Franchise After ‘Starfleet Academy’s Cancelation The Star Trek Series Decades In The Making Lasted Just Over 2 Months Why Starfleet Academy's Cancelation Has Me Worried About The Star Trek Franchise ‘Star Trek: Starfleet Academy’ Offers the Franchise a Unique Way Forward STAR TREK’s TV Future Explained by Alex Kurtzman Amid Paramount Skydance Changes — GeekTyrant Subspace Chatter STAR TREK: YEAR ONE Has Already Been Pitched To Paramount Skydance STAR TREK: YEAR ONE Pitch Has Officially Reached Paramount Skydance -CBR “Star Trek: Year One” Has Been Pitched – Dark Horizons Star Trek: Starfleet Academy Fan Petition Hits Milestone After Paramount+ Cancellation Petition · Renew ‘Star Trek: Starfleet Academy' for a third season – United Kingdom · Change.org Star Trek: Scouts Final Episodes Released on YouTube Star Trek: The Next Generation Star Remembers When They Weren’t Real Trek | Den of Geek NickALive!: The 16th Anniversary Bundle! | Star Trek Online 25 Years Later, Star Trek Has Revealed The Hidden Reason Starfleet Actually Began PREVIEW — Inside IDW's THE ART OF STAR TREK: LOWER DECKS – TrekCore.comAndy Weir Apologizes To Alex Kurtzman After Slamming Modern STAR TREK ‘Project Hail Mary' Author Stirs Controversy Over Failed Star Trek Pitch, Then Apologizes To Alex Kurtzman – TrekMovie.com Andy Weir ‘Star Trek’ Comments Draw Fire From Author Don Winslow ‘Star Trek’: How The Beatles Inspired Kirk and Spock's Reboot Bond Leonard Nimoy’s Positive Reaction To Star Trek: DS9’s ‘Trials and Tribble-ations’ Star Trek: Prodigy Wins Emmy Award Land The Shuttlecraft Galileo by Brian Mix — Kickstarter STAR TREK: STRANGE NEW WORLDS Season 4 Premiere Expected In Late Summer Toy Fair ’26: Nacelle announces Lucille Ball & Gene Roddenberry action figures Action Figure Insider » Nacelle Toys Reveal New Star Trek Products at #Wondercon2026 Here are links to 57  additional stories.broken out by series, movies and other categories. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] 57 Years Ago Today, Star Trek Released A Time Travel Masterpiece That The Franchise Has Never Beaten – ComicBook.com ‘Star Trek' Actress Admits She Had a Crush on William Shatner Star Trek: The Next Generation (1987 – 1994) [7 seasons] 10 Star Trek: The Next Generation Episodes To Skip On A Rewatch Star Trek: TNG’s Chain of Command Is Mandatory Viewing for Every Sci-Fi Fan Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] One Of Star Trek's Best Episodes Was Created Out Of Spite Star Trek: Voyager (1995 – 2001) [7 seasons] The Star Trek Episode That Only Exists Because Of A Sex Joke STREAMING SERIES AND MOVIES (in order of premiere) Star Trek: Picard (2020 – 2023) [3 seasons] Why 1 Returning Star Trek: The Next Generation Star Was Disappointed by Picard Season 3's Reunion – ComicBook.com ‘Star Trek: Picard’ Never Confirmed ‘Voyager’s Alternate Future Captain La Forge Reveal Star Trek’s Marina Sirtis Explained Why Comparing Her Experience On Picard Season 3 To TNG Was ‘Depressing’ | Cinemablend Star Trek: Lower Decks (2020 – 2024) [5 seasons] Star Trek: Lower Decks Made An Abandoned Vulcan Character Franchise Canon Star Trek: Strange New Worlds (2022 – present) [4th season yet to premier, 5th/final season filmed] Star Trek director ‘was very proud of’ arguably the worst Strange New Worlds episode STAR TREK: STRANGE NEW WORLDS Season 4 Promises “Classic” Episodes Alongside Bold New Experiments Star Trek: Starfleet Academy [2026 – present] [season 2 will end series] Star Trek Officially Confirms It Now Follows One of the Oldest Star Wars Rules – ComicBook.com Starfleet Academy Showrunner Teases Season 2: ‘The Dynamics You Thought Were Going to Be One Way Forever Start to Slowly Shift' – IGN REVIEW – Star Trek: Starfleet Academy “Rubincon” – Trek Central Starfleet Academy is Star Trek (despite what so-called fans would have you believe) Star Trek's Most Divisive Spin-Off Warps Past a Major Streaming Milestone Starfleet Academy's Finale Improved Because It Removed Terrible Star Trek Characters Star Trek: Starfleet Academy season 1 finale provides 6 unexpected glimpses of the future Star Trek: Starfleet Academy Is The Greatest Argument For The Return Of Long TV Seasons Yes, There Will Be a Starfleet Academy Season 2. Here’s What We Know About It – Reactor KUOW – ‘Starfleet Academy’ isn’t for everybody, but ‘Star Trek’ still is (Did ‘Star Trek’ jump the targ?) 39 Years Later, The Star Trek Franchise Just Put Itself On Trial — Again Jonathan Frakes Reacts to ‘Absurd’ Star Trek: Starfleet Academy Gag The United Federation of Planets Has a War College Now — Are We Gonna Talk About It? – Reactor Star Trek just fumbled what could have been an all-time villain reveal Star Trek: 3 Best Things About Starfleet Academy Season 1 (& The 5 Worst) – ComicBook.com Starfleet Academy season 1 finale makes it painfully obvious what's coming for the Doctor in season 2 Star Trek: Starfleet Academy Calls Out a Missing Piece of Starfleet Canon 60 Years Later Star Trek actor was Jonathan Frakes’ ‘secret weapon’ on Starfleet Academy Star Trek icon praises Starfleet Academy’s ‘great’ Khionian actor unannounced “Star Trek: Legacy” series Star Trek: Legacy Is ‘Never Gonna Happen’ Says TNG Icon Trek series that never were, for one reason or another, [such as “Phase II”] The Lost ‘Star Trek' Movies and Shows That Almost Happened—and the Stories Behind Them THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: First Contact (1996) Tom Hanks Wanted To Play An Extremely Important Star Trek Character Fourth Kelvin-timeline movie [cancelled in 2025 after many false starts] Why Star Trek 4 Isn't Happening OTHER MEDIAStar Trek video games/board games We Boldly Go Hands-On With Star Trek: Infection & Live To Tell About It Star Trek toys/collectibles/other merchandise March STAR TREK Merch Roundup: Klingon Weapons, STARFLEET ACADEMY Pins, New EXO-6 Figures, and More! – TrekCore.com Star Trek Comics/graphic novels/magazines Star Trek: The Last Starship #8 Exclusive Preview Star Trek: The Last Starship #6 – Comic Book Preview MISCELLANEOUS Paramount+ / Paramount Skydance David Ellison On Cost Savings, Growth, The Tech Stack & AI As WBD Merger Star Trek related science news A Modest Proposal: Star-Trek-like Communicator Badges for Siri | Scientific American Franchise-wide/Miscellaneous All 10 Star Trek Series Finale Episodes, Ranked – AOL All 14 Star Trek Movies Ranked According To Rotten Tomatoes Paramount has a Star Trek Strategy Problem. Here Are Five Ways to Fix It. 10 essential Star Trek episodes to watch after Starfleet Academy season 1 Every Star Trek First Season Ranked Worst to Best – Reactor Everything We Know About the Future of ‘Star Trek’ Column | What ‘Star Trek' teaches us about the 21st century – The Pitt News Rod Roddenberry on Carrying Forward the STAR TREK Legacy – Nerdist The 10 Best Star Trek Episodes of All Time – ComicBook.com Where did ‘Star Trek’ go? And what does it mean for the future of Paramount – and movie theaters? – East Idaho News 10 Most Uncomfortable Star Trek Scenes Of All Time Star Trek Should Boldly Go Back To Network TV ‘Star Trek: The Next Generation’ Trivia: Take the World’s Hardest Quiz Actor Watch Jonathan Frakes Says STARFLEET ACADEMY Could Be His Last Time Directing STAR TREK — GeekTyrant Shatner's 95th sparks global Star Trek party Shatner Reveals Why He Avoids Watching Star Trek Main Mission, Part 2 (with an appropriate sound effect) Star Trek: The Cruise 2026 End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast (MUSIC IN) If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Don’t put on the red shirt! END RECORDING – HAILING FREQUENCIES CLOSED

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91)A U.S. federal court has largely denied a joint motion to dismiss Quantum BioPharma's USD $700 million lawsuit against CIBC World Markets and RBC Dominion Securities, which alleges illegal market manipulation through spoofing practices. The ruling marks a significant legal milestone for the company, allowing the case to move forward. Beyond the courtroom, Quantum continues to advance its drug development pipeline targeting multiple sclerosis and alcohol misuse disorders.Tartisan Nickel Corp. (CSE: TN) (OTCQX) (FSE)Tartisan has proposed a $1 million non-brokered flow-through financing at $0.38 per share to support ongoing exploration at its Kenbridge nickel-copper-cobalt project in Northwestern Ontario. The financing reflects continued commitment to advancing a critical minerals asset in a region increasingly viewed as strategically important for battery metals and supply chain security.Nine Mile Metals Ltd. (CSE: NINE) (OTC PINK: VMSXF) (FSE: KQ9)Nine Mile reported strong certified assay results from drill hole WD-25-2B at the Wedge Mine in the Bathurst Mining Camp. The hole returned 3.17% copper equivalent over 15.00 metres, including a higher-grade interval of 5.99% copper equivalent over 6.84 metres. Visible high-grade copper mineralization at the base of the hole suggests further upside potential as the company prepares for its Phase 3 drill program in May.NevGold Corp. (TSX-V: NAU) (OTCQX: NAUFF) (Frankfurt: 5E50)NevGold achieved up to 99% gold recovery in Phase II metallurgical testing on oxide antimony-gold material at its Limousine Butte Project in Nevada. Sequential leaching for antimony and gold demonstrated minimal impact on gold recoveries, supporting the potential for a combined antimony-gold operation. The company also identified additional antimony mineralization at surface within a historical waste dump.Yukon Metals Corp. (CSE: YMC) (FSE: E770) (OTCQB: YMMCF)Yukon Metals released results from its first drill program at the Star River property near the past-producing Ketza mine in the Yukon. Drilling intersected 11.7 g/t gold within a polymetallic vein system, alongside values of up to 183 g/t silver and 10.6% lead. A drone magnetic survey outlined a 1-kilometre structural corridor, and the company expanded its land position by acquiring the historic Stump silver-lead claims along the same trend.Bottom Line: Today's headlines highlight strong momentum across the small-cap mining and biotech sectors, from significant court developments and financing initiatives to high-grade drill results and advancing metallurgical programs.Stay ahead of the market by following AGORACOM for more breaking small-cap news and insights.And don't forget to check out our podcast for deeper dives into the stories shaping the small-cap market.

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Nextech3D.AI Corporation (CSE: NTAR) (OTCQB: NEXCF) (FSE: 1SS)CEO Evan Gappelberg has purchased an additional 500,000 common shares on the open market at $0.12 CAD, bringing his total ownership to more than 30 million shares. The insider buy reinforces management's confidence in the company's AI-powered event technology platform, which has reported 95% gross margins and 59% year-over-year revenue growth. With 50 new enterprise contracts signed since January and profitability achieved at its Krafty Labs division, the company believes its current valuation does not reflect its growth trajectory.Thunderstruck Resources Ltd. (TSXV: AWE) (OTC: THURF)Zhaojin International Gold Co. Ltd. (SZSE: 000506), one of China's leading gold producers with annual output of 600,000 to 700,000 ounces, is making a strategic investment in Thunderstruck for approximately 19.99% of the company at $0.11 per share, totaling about CDN$1.56 million. This marks Zhaojin's first investment in an exploration company and validates Thunderstruck's district-scale gold, silver, zinc and copper portfolio in Fiji. Zhaojin will receive a board seat and the right to appoint a Vice President of Exploration.Advanced Gold Exploration Inc. (CSE: AUEX) (FSE: ZF2) (OTCID: AUHIF)The 2025 drill program at Buck Lake has confirmed massive sulphide mineralization along a 3,000-metre electromagnetic corridor in Ontario's Batchawana Greenstone Belt. Drill hole BL-25-01 returned 9 metres averaging 510 ppm copper, with a peak of 1,180 ppm. BL-25-03 intersected 16.5 metres averaging 545 ppm copper, with highs up to 1,200 ppm. The polymetallic VMS signature, comparable to systems such as Kidd Creek and the Horne Mine, suggests the current shallow drilling may represent only the upper portion of a larger mineralized structure.Minaurum Silver Inc. (TSXV: MGG) (OTCQX: MMRGF) (FSE: 78M)Minaurum's Phase II drill program at the Alamos Silver Project in Sonora, Mexico, has delivered high-grade results from the Quintera Vein Zone. Hole AL26-180W returned 5.30 metres grading 570 g/t silver, including 2.50 metres at 1,024 g/t silver. Hole AL26-188 intersected 5.80 metres at 581 g/t silver. Notably, Quintera was not included in the company's initial resource estimate and is expected to be incorporated into an updated estimate in the second half of 2026. With six rigs active on a fully funded 50,000-metre program, Minaurum continues to expand high-grade zones across multiple vein systems.Bottom Line: Today's headlines highlight insider conviction, international strategic investment, and strong drill results across the small-cap mining and technology sectors. From a CEO increasing his personal stake to a major Chinese gold producer backing a Fiji-based explorer, these developments point to growing confidence in companies demonstrating tangible operational progress.Stay ahead of the market by following AGORACOM for more breaking small-cap news and insights.And be sure to check out our podcast for deeper dives: https://open.spotify.com/show/74mVPkfalaWXFYY65A2XLM

Pancreatic cancer remains one of the most difficult cancers to treat, largely because its dense tumor microenvironment makes it difficult for chemotherapy drugs to reach their target. This often leads to poor patient outcomes and underscores the urgent need for new therapeutic strategies to overcome these barriers. In this episode of Curing with Sound, Jae Young Lee, MD, PhD, professor and researcher at Seoul National University Hospital, shares his work exploring focused ultrasound as a noninvasive treatment option for pancreatic cancer. He explains how this technology creates subtle mechanical stress within the tumor, helping to open up its structure so chemotherapy can work more effectively. Dr. Lee also shares encouraging results from his Phase II clinical trial and looks ahead to a pivotal Phase III study, offering new hope for improving patient outcomes. Discussion highlights: A New Treatment Strategy: Focused ultrasound technology shows promise for addressing the unique challenges of pancreatic cancer, enabling precise tumor targeting while preserving critical surrounding structures. From Research to Reality: Learn how Seoul National University Hospital, a designated Focused Ultrasound Center of Excellence, is integrating this technology into clinical care while advancing research across oncology, neurosurgery, and pain management. Seoul National University Hospital Website EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/    

This week, we’re wrapping up Path of Vengeance by Cavan Scott and discussing the manga Edge of Balance: Precedent. Join us as we discuss Marda’s character arc, transitioning into Phase III of the High Republic project, and our feelings about Phase II overall. For a list of Black-owned bookstores to order from, now and always, […]

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Featuring an interview with Dr Ravin Ratan, including the following topics: Efficacy and safety of long-term continuous nirogacestat treatment in adults with desmoid tumors: Results from the Phase III DeFi trial (0:00) Onset and resolution of ovarian toxicity with nirogacestat treatment for desmoid tumors: Updated safety analyses from the DeFi trial (4:37) Subgroup analysis of the Phase II part of the RINGSIDE Phase II/III trial of varegacestat for desmoid tumors (7:39) Surgical management of desmoid tumors; cryotherapy in the treatment of extra-abdominal desmoid tumors (10:30) CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics: VAYHIT1: A multicenter randomized, double-blind, Phase III trial evaluating ianalumab versus placebo in addition to first-line corticosteroids for patients with primary immune thrombocytopenia (ITP) (0:00) Secondary analysis results from VAYHIT3, a Phase II study of ianalumab for patients with primary ITP previously treated with at least 2 lines of therapy (8:15) Improved health-related quality of life and bleeding scores with the oral Bruton tyrosine kinase inhibitor rilzabrutinib in the open-label period of the multicenter Phase III LUNA 3 study for adults with ITP (12:23) Romiplostim for chemotherapy-induced thrombocytopenia in patients with colorectal, gastroesophageal and pancreatic cancer: A global Phase III randomized, placebo-controlled trial (16:01) CME information and select publications

The second ousting of Vinay Prasad from FDA in the past eight months won't lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest BioCentury This Week podcast, Washington editor Steve Usdin lays out why the former CBER director was pushed out at FDA and what's next for the agency following his departure.BioCentury's editors also discuss the next wave of therapies for idiopathic pulmonary fibrosis, including whether new candidates might go beyond slowing disease to halt or even reverse progression, the biological complexity that makes fibrosis so challenging, and what the 20-plus Phase II programs could teach the field about fibrosis biology.Also up for discussion were recent clinical wins — as well as more complicated readouts — from psychedelic therapies; plus the latest data updates from obesity treatments, with a focus on amylin agonists.View full story: https://www.biocentury.com/article/658698#FDA #IdiopathicPulmonaryFibrosis #PsychedelicTherapies #ObesityDrugs #AmylinAgonists00:00 - Introduction01:56 - Prasad's Departure15:27 - Fibrosis Therapies23:35 - Psychedelics Clinical Catalysts28:24 - Obesity UpdatesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Tim Shearcroft,  CEO and Co-Founder of BP Silver Corp. (TSXV: BPAG), joins me for a review of some bonanza-grade final assay results from the remaining eight drill holes of its eleven-hole Phase I drill program at the Cosuño Silver Project in Bolivia. We discuss the follow up geophysics survey and goals of the Phase II exploration program. Additionally, the Company is working on finalizing the title at their Titiri Project, located in a major under-explored silver belt with Tier 1 discovery potential.   Phase I Highlights:   Drilling intersected multiple zones of high-grade silver mineralization at the Pocañita Chica target: Diamond Drill Hole # CO-0008 returned 5m @ 600.4 g/t silver, including 1m @ 1655 g/t silver; Diamond Drill Hole # CO-0009 returned 1m @ 526 g/t silver and 6m @ 147 g/t silver. The Program achieved its primary objective of confirming silver mineralization within the lithocap beneath surface geochemical anomalies, materially de-risking Cosuño. Silver mineralization was intersected in all four targets tested across an approximately 2.7 km NE-SW corridor, confirming the presence of a robust silver and polymetallic system which remains open for expansion along strike and at depth.   The Program successfully tested key zones along a 2.7 km structural trend, returning significant silver intercepts at the 4 targets tested to date (Figures 1 to 3):   Pocañita Chica – Broad mineralized envelopes with high-grade silver intervals hosted in hydrothermal breccias. Pocalleta – Structurally controlled vein mineralization confirming depth potential. Jalsuri – High-grade silver intercepts with gold 2.7 km northeast of Pocañita Chica, indicating district-scale continuity. Benhur – Additional silver mineralization along the same structural corridor.   Additionally, their team is working with the government to finalize obtaining the title to begin exploration on their Titiri Project.  Titiri was staked over a large land concession containing outcropping mineralization historically explored by ASARCO.  This Project contains a 2.5km-long silver-lead-zinc zone, with excellent historical trench results, that was never drilled. Titiri is a very High Priority structural setting at the intersection of several major crustal-scale faults, along which multiple deposits occur.  There is a MOU in place with local communities, and they'd like to get on the ground for exploration in mid-2026.     If you have any questions for Tim regarding BP Silver, then please email those into me at Shad@kereport.com.   Click here to follow the latest news from BP Silver Corp   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today.Arras Minerals (TSXV: ARK) reported one of its strongest drill results yet at the Elemes Project in Kazakhstan, intersecting 52.4 metres grading 2.11% copper-equivalent, including 1.49 g/t gold and 0.58% copper. The high-grade interval sits within a broader 446-metre mineralized zone, suggesting significant scale. The Berezski Central target also returned 135 metres grading 0.43% copper-equivalent starting near surface. With the Phase II program expanded from 20,000 to 30,000 metres and four drills turning soon, Arras is accelerating toward what management believes could be the core of a large copper-gold porphyry system.Astra Exploration (TSXV: ASTR) announced a major new silver-gold discovery at its La Manchuria Project in Argentina. The company hit 6.3 metres grading 837 g/t silver and 3.32 g/t gold, including ultra-high-grade intervals of up to 3,309 g/t silver and 11.45 g/t gold over 1 metre. The new Basalto Zone is a previously untested parallel vein system that remains open in all directions. With additional assays pending and a fully funded 5,000-metre follow-up program set to begin, Astra is expanding its footprint in one of Argentina's most prolific precious metals districts.West Red Lake Gold (TSXV: WRLG) delivered exceptional high-grade results from the Austin 904 Complex at the Madsen Mine in Ontario's Red Lake district. Highlights include 219.73 g/t gold over 4.8 metres, 148.36 g/t over 3 metres, and 133.13 g/t over 2.5 metres, with visible gold observed in several intervals. These triple-digit grades support the company's strategy of defining high-grade lenses that could enhance near-term mine planning and support redevelopment momentum in one of Canada's historic gold camps.McFarlane Lake Mining (CSE: MLM) expanded mineralization at its Juby Gold Project in Ontario with a broad intercept of 95.4 metres grading 1.36 g/t gold at the Golden Lake Zone, including 55.4 metres at 1.96 g/t and 9.9 metres at 3.22 g/t. The intersection lies outside the current resource model, pointing to potential resource growth. The company is adding a second drill and advancing environmental baseline work, positioning Juby for an accelerated exploration phase in the Abitibi Greenstone Belt.Aztec Minerals (TSXV: AZT) reported additional step-out success at its Tombstone Project in Arizona, intersecting 44.1 metres grading 0.86 g/t gold equivalent, including 6.1 metres at 3.72 g/t gold equivalent. Another hole returned 40.2 metres at 1.09 g/t gold equivalent, including 4.6 metres at 9.86 g/t. The results connect the Contention and Westside zones, extending mineralization to over one kilometre along strike. With 53 RC holes completed and more assays pending, Aztec continues to expand the footprint of its shallow oxide gold-silver system.For more breaking small-cap news, interviews and in-depth coverage, follow AGORACOM here and subscribe to the AGORACOM Podcast for exclusive CEO interviews and real-time market insights.

Listen below or click here for full show notes Main Mission, Part 1 Star Trek: Starfleet AcademySeason 1, Episode 7“Ko’Zeine”Written by Alex Taub & Eric Anthony GloverDirected by Andi Armaganian Subspace Chatter Star Trek: Starfleet Academy Season 2 Wraps Filming! – Trek Central Land The Shuttlecraft Galileo by Brian Mix — Kickstarter Star Trek: Starfleet Academy Showrunners on Deep Space Nine Star Trek Finally Closes a Plot Hole That's Haunted The Original Series 59 Years Later The twelve newly announced ships joining the collection include: The Texas-class USS Aledo from Lower Decks The android-manned Synth attack ship from Picard The USS Damocles, the Klingon-constructed false Federation starship from Strange New Worlds The USS Athena from Starfleet Academy A one-nacelled Freedom-class variant of the USS Cerritos The classic Shuttlecraft Galileo from The Original Series The USS Kelcie Mae from Strange New Worlds An XL-sized model of the USS Cerritos with its hull removed The Nova Flyer vessel from Prodigy The USS Adventure from Strange New Worlds A Gorn Hunter ship from Strange New Worlds An XL-sized USS Protostar featuring a deployed proto-warp drive Fanhome Announces Expansion to STAR TREK STARSHIPS Collection, with Additions from STARFLEET ACADEMY, STRANGE NEW WORLDS, and More Quick mention of the Warner Bros., Netflix, Paramount continuing saga article. Here are links to 83 additional stories.broken out by series, movies and other categories. You’ll find articles on everything from How Lucille Ball Saved Star Trek to the 1980’s attempt to make a Starfleet Academy movie.. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] The Original Drafts for Star Trek’s Opening Narration – Neatorama How Lucille Ball Saved ‘Star Trek’ But Lost Her Studio (Exclusive) | Woman’s World Star Trek: The Next Generation (1987 – 1994) [7 seasons] Michael Dorn almost quit Star Trek The Next Generation after just two seasons in the role of Worf – 3DVF Why ‘Star Trek' Star Couldn't Sleep While Playing His Iconic Role – Parade Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] Star Trek: Deep Space Nine Was Inspired By This Hit ’50s Western Series Star Trek: Voyager (1995 – 2001) [7 seasons] ‘Star Trek' Icon, 72, Admits His Character’s Beloved Trait Was a ‘Mistake’ Star Trek: Enterprise (2001 – 2005) [4 seasons] Why Star Trek Bosses Were Afraid Scott Bakula Would Pass On Enterprise Until The Last Minute Why Was Star Trek: Enterprise Cancelled and Can It Be Revived? – Cancelled Sci Fi STREAMING SERIES AND MOVIES (in order of premiere) Star Trek: Discovery (2017 – 2024) [5 seasons] Star Trek: Discovery Cancellation Was Surprising, Says Mary Wiseman Star Trek: Strange New Worlds (2022 – present) [4th and 5th seasons] Jonathan Frakes On Directing Jack Quaid’s Hilarious ‘Riker Maneuver’ In Star Trek Crossover Star Trek: Starfleet Academy [2026 – present] [renewed for second season] REVIEW – Star Trek: Starfleet Academy “Come, Let’s Away” – Trek Central ‘Starfleet Academy’ Decides Everyone Needs a Harsh Lesson Star Trek’s Divisive New Series Just Proved The Doubters Wrong Star Trek: Starfleet Academy Episode 6 Review – Come, Let's Away | Den of Geek Star Trek: Starfleet Academy Episode 6 Review – Return to the Miyazaki! – IGN Has ‘Star Trek: Starfleet Academy’ just unleashed its very own Khan? | Space Star Trek Finally Reveals Voyager’s Official Replacement – ComicBook.com Star Trek’s New TV Series is Changing the Galaxy More Than Any Other Show Before It – ComicBook.com Star Trek: Starfleet Academy Proves Just How Influential Spock Truly Was Did Starfleet Academy nail its ‘love letter’ to Star Trek: DS9? After Starfleet Academy’s DS9 Episode, I Know How The Star Trek Series Could Bring Back A Legacy Character | Cinemablend I Was Surprised At How Real Star Trek: Starfleet Academy's Mind Space Was, But The Stars Said It Had A Funny Downside Starfleet Academy Finally Finds The Sweet Spot For Storytelling Starfleet Academy Can Succeed Where Every Other New Star Trek Series Has Failed NickALive!: The Cadets Return Home for the Holidays in New ‘Star Trek: Starfleet Academy’ Episode ‘Ko'Zeine’ | First Look Star Trek's Epic New Klingon Villain Return Officially Addressed by Star – ComicBook.com Starfleet Academy Episode 7 “Ko’Zeine” Pits Ambition Against Family Duty as Cadets Return Home + 10 New Photos – TREKNEWS.NET | Your daily dose of Star Trek news and opinion Star Trek: Starfleet Academy’s Hidden Connection To Chris Pine’s Captain Kirk Star Trek Officially Confirms a Major Klingon Theory (& Sets Up a New Problem) – ComicBook.com Paramount+'s Unexpected Sci-Fi Hit Officially Wraps Season 2 Very Soon [Exclusive] Interview — STAR TREK: STARFLEET ACADEMY's George Hawkins on His “Fishboy” Alter Ego, Cadet Darem Reymi – TrekCore.com ‘Star Trek’ Star Says He Was ‘Scared' to Play His Groundbreaking Role — Here's Why Star Trek: DS9 actor was ‘amazing’ to work with on Starfleet Academy Starfleet Academy Episode 7: One Wedding and a Burglary Star Trek: Starfleet Academy’s George Hawkins Admitted Darem’s Episode Made One ‘Brutal’ Change ‘Starfleet Academy’ Gives Its Kids (and Itself) the Grace to Find Their Own Path 61 Years Later, Star Trek Is Taking A New Approach To The Captain Kirk Question 33 Years Later, Star Trek Just Released a Secret Sequel to a Classic Next Generation Episode – ComicBook.com Healing Old Wounds and New Beginnings in Starfleet Academy Episode 8 “The Life of the Stars” + 17 New Photos – TREKNEWS.NET | Your daily dose of Star Trek news and opinion ‘Star Trek: Starfleet Academy’ Fan Backlash Explained | The Mary Sue ‘Star Trek: Starfleet Academy’: Bella Shepard Reveals How Genesis’ Setback Just Set up Season 2 33 Years On, Star Trek Officially Reverses a Decision The Next Generation Admitted Was a Mistake – ComicBook.com Star Trek: Starfleet Academy Actors Wrao Season 2 Filming: Impact On Paramount+ Franchise As ‘Star Trek’ Nears 60, Showrunners Say It Must ‘Bring Something Back’—Here's What They Mean – Parade Star Trek: Discovery’s Captain Burnham Creates Dilemma For Star Trek: Starfleet Academy Star Trek returns to Top 10 charts on Friday the 13th (& Paul Giamatti seems to be why) New 88% RT Star Trek Show Gets Exciting Season 2 Update STAR TREK: STARFLEET ACADEMY Gives VOYAGER’s Doctor New Role – Nerdist Alex Kurtzman Learned to Put the Stars of ‘Starfleet Academy’ in Danger From an Unlikely Source Unannounced “Star Trek: United” A Star Trek Producer Has A Perfect Idea To Bring Back Captain Archer Trek series that never were, for one reason or another, [such as “Phase II”] ‘Star Trek Phase II’: The Lost ’70s Series That Shaped the Franchise | Woman’s World THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: Generations (1994) Tom Hanks Nearly Changed the Best Star Trek Movie Ever Made Star Trek (2009) Starfleet Academy subtly pays homage to J.J. Abrams’ Star Trek (2009) Star Trek into Darkness (2013) Star Trek Into Darkness Director J.J. Abrams Has One Big Regret About The Sequel Karl Urban’s Script Critique Led To One Of Star Trek Into Darkness’ Funniest LinesTrek movies that never were, for one reason or another, [such as Tarantino’s movie] The Lost ‘Star Trek’ Starfleet Academy Movie: An Inside Look (Exclusive) | Woman’s World The Lost 1970s ‘Star Trek' Movie That Almost Changed Spock Forever | Woman’s World OTHER MEDIAStar Trek video games/board games Everything We Know About Star Trek: Across the Unknown – Trek Central NickALive!: Star Trek: Voyager – Across the Unknown | Personal Log: Tom Paris | English | Daedalic Entertainment Ezri Dax returns to Star Trek Online to face a Lovecraftian threat Star Trek toys/collectibles/other merchandise Nacelle Showcases STAR TREK Action Figure Paint Masters, Holodeck, TOS Bridge Playset, and More at Toy Fair 2026 – TrekCore.com Star Trek Comics/graphic novels/magazines After 37 Years, Star Trek Makes Its Biggest Starfleet Retcon Yet With the Borg NickALive!: Star Trek: Starfleet Academy–Lost Contact Trailer | IDWPublishing Ensign’s Log: Nyota Uhura shines on in STAR TREK: DEVIATIONS – THREADS OF DESTINY #1 REVIEW – Star Trek: Deviations – Threads of Destiny – Trek Central The Future of ‘Star Trek’ Comics Is Ready for a New Next Generation (Exclusive) IDW Launching Two New STAR TREK Comic Series in September, Additional CELEBRATIONS One-Shots, and More! – TrekCore.com MISCELLANEOUS Franchise-wide/Miscellaneous Star Trek: Everything We NOW Know About The Lost Era Star Trek: 10 Episodes That Are UNWATCHABLE Now 28 Memorable ‘Star Trek’ Crossovers Across 60 Years | Woman’s World ‘Star Trek Next Generation’ Cast Then and Now: 35 Years Later | Woman’s World 10 Worst Star Trek Ship Designs, Ranked ‘Star Trek: Starfleet Academy' wants you to flash the Vulcan salute at Pier 39 Some Star Trek Fans Complain About The Franchise's Direction, But I Need To Hit Back After Watching Final Frontier For The First Time | Cinemablend The Kelvin Timeline's Lasting Legacy: How Abrams’ Star Trek Trilogy Shaped the Franchise's Streaming Era – TREKNEWS.NET | Your daily dose of Star Trek news and opinion Convention news/fandom Star Trek celebrates 60 years with star-studded cruise – CBS News The Lost Story That United the Original ‘Star Trek’ and ‘Doctor Who’ | Woman’s World How ‘Star Trek' Fans Saved the Show With a Million Letters (EXCLUSIVE) | Woman’s World Actor Watch STAR TREK: VOYAGER's Captain Janeway Defends STARFLEET ACADEMY's Captain Ake From Online Trolls Beam Me Up, Sulu Directors on Star Trek’s Ongoing Cultural Relevance Leonard Nimoy | All Star Trek James Doohan Military Service: ‘Star Trek’ Scotty’s Secret D-Day Story | Woman’s WorldPassings ‘Star Trek' Actor John Wheeler Dead at 95 Main Mission, Part 2 Star Trek: Starfleet AcademySeason 1, Episode 8“The Life of the Stars”Written by Gaia Violo & Jane MaggsDirected by Andi Armaganian Our Town 2003 Broadway Production Paul Newman as Stage Manager – YouTube Time to refill the dilithium chamber and warp on out of here! End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Until next time, on behalf of my absent co-hosts, Chuck, Kreg and myself, and my special guest, Gary, I’m Clinton, thanking you for listening. And, as we always say here on “The Topic Is Trek” Don’t put on the red shirt! END RECORDING – HAILING FREQUENCIES CLOSED

Discover how to lose weight without Ozempic using 5 evidence-backed strategies. This episode breaks down why insulin resistance is the real driver of weight gain and how cutting processed foods, eating only when hungry, fasting, weight resistance training, and detoxification can help you lose weight naturally and sustain it long-term — no prescription required. FEATURED PRODUCT The Good Poops Protocol is designed to support the exact systems discussed in this episode — liver detoxification, gut health, and blood sugar regulation. 

We’re starting our read of Cavan Scott’s Path of Vengeance, the final novel in Phase II of the High Republic. We talk about ghosts, unraveling the Mother’s identity, and what Marda Ro has been up to (spoiler alert: it’s cult shit). For a list of Black-owned bookstores to order from, now and always, click here. […]

What if one of the most powerful tools for detoxification, brain health, hormone balance, and healthy aging was something you could grow in your kitchen? In this science-packed episode of The Girlfriend Doctor Podcast, Dr. Anna Cabeca sits down with renowned nutritional biochemist Dr. Jed W. Fahey — the pioneering researcher behind the discovery of the extraordinary chemoprotective power of broccoli sprouts. After 27 years at Johns Hopkins University School of Medicine, where he directed the Cullman Chemoprotection Center, Dr. Fahey explains why sulforaphane — derived from glucoraphanin found abundantly in broccoli sprouts — activates your body's own protective systems at the cellular level. Dr. Anna shares her personal clinical experiences using sulforaphane-rich compounds to support detoxification pathways, immune resilience, abnormal Pap smears, skin health, neurocognitive protection, and hormone balance — especially in midlife women. In this episode, you'll learn: What sulforaphane actually is (and why it matters) How it activates phase II detoxification pathways Why broccoli sprouts are more potent than mature broccoli Neuroprotective and brain benefits Research around skin and melanoma protection Dosage guidance for sprouts vs. supplements How to safely incorporate them into your daily routine This isn't about trendy superfoods. It's about turning on your body's built-in defense systems. Small daily choices. Powerful cellular protection.   Key Timestamps 00:01 – Welcome & why broccoli sprouts matter 03:14 – Broccoli sprouts vs. mature broccoli: what's the difference? 06:21 – What exactly is sulforaphane? 09:24 – Phase II detoxification explained simply 15:23 – Dr. Anna's powerful clinical case using sulforaphane 17:31 – Brain health & neurocognitive benefits 24:43 – How much should you take daily? 31:24 – Skin health & melanoma research 33:35 – Food vs. supplement: dosage considerations 42:13 – One big takeaway for healthy aging   Memorable Quotes "This isn't about complicated science. It's about small daily choices that protect your cells." "Sulforaphane switches on your body's own protective systems." "Broccoli sprouts are foundational — not optional — for longevity." "We want to help and do no harm." "You were made for vitality."   Connect With Our Guest Dr. Jed W. Fahey

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Chief Policy Officer Michael Koplow and Distinguished RAND Israel Policy Chair Shira Efron. The trio discuss this week's summit meeting in Washington between President Trump and Prime Minister Netanyahu, the chances of negotiations with Iran actually succeeding, the likely gaps between the U.S. and Israel over any potential deal, the threat of a military attack if diplomacy fails, how Phase II in Gaza is going, the recent damaging steps taken by the Israeli government on the West Bank, and more.Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber and Israel Policy Forum Director of Strategic Initiatives and IPF Atid Shanie Reichman discuss the state of play in the Iran crisis, potential upcoming U.S.-Iran talks and the prospects for their success, Ran Gvili z”l's return home last week and the closure of the hostage saga, the real start of Phase II in the Gaza ceasefire and the mechanics behind it, Zohran Mamdani and the Jewish community one month in, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

What will Phase II of Trump's plan for Gaza look like on the ground? Who's  in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing structure — Trump's “Board of Peace,” the Gaza Executive Committee, a Palestinian technocrat government, and an International Stability Force — and explain what will actually matter on the ground: money, security control, and whether Hamas truly disarms. They also assess Israel–U.S. friction, the odds of renewed fighting, what daily life in Gaza looks like right now, and how all of this collides with Israeli election politics.In this episode...- Understanding the Governance of Gaza- Who Holds Power in Gaza? Money, Security, and Accountability- Hamas After the War- Phase Two, the Yellow Line, and Israeli Withdrawal- The International Stability Force Explained- Life in Gaza Right Now- Gaza Meets Israeli Politics- The Bigger Regional PictureFrom the episode:This episode was sponsored by The Shalom Hartman Institute: Learn more about the Community Leadership Program at https://go.hartman.org.il/CLP-CMBMore Ark Media:Want to join Ark Media? Check out our careers page for new openings.Subscribe to Inside Call me BackListen to For Heaven's SakeListen to What's Your Number?Watch Call me Back on YouTubeNewsletters | Ark Media | Amit Segal | Nadav EyalInstagram | Ark Media | DanX | DanDan Senor & Saul Singer's book, The Genius of IsraelGet in touchCredits: Ilan Benatar, Adaam James Levin-Areddy, Brittany Cohen, Martin Huergo, Mariangeles Burgos, and Patricio Spadavecchia, Yuval Semo 

What will Phase II of Trump's plan for Gaza look like on the ground? Who's  in charge of Gaza now, and who's paying the bills? Dan is joined by Ark Media contributors Nadav Eyal and Amit Segal to cut through the fog around “phase two” of the Gaza plan. They break down the new governing […]

Roche/Genentech announced on June 15–16, 2025 that prasinezumab — an anti-α-synuclein monoclonal antibody — will enter Phase III trials for early Parkinson's disease after mixed but encouraging Phase II signals.  In this episode (watch on YouTube) we explain the biology behind α-synuclein targeting, summarize the PASADENA and PADOVA findings (what was missed and what looked promising), discuss safety issues and trial design challenges, and speak with experts/patients about realistic timelines and hopes for disease-modifying therapies To follow trials like this and to have customized information and results delivered to you directly, consider signing up to try Turnto and the AI sidekick Turny. Sign up here and use the promo code PDEDUCATION for a 10% discount: https://www.turnto.ai/sidekick?fpr=pdeducation Help to support this channel and out efforts to educate the world about Parkinson's Disease and get access to personalized content: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join  https://www.patreon.com/pdeducation Please be sure to give support to our channel sponsors: Comfort Linen: https://comfortlinen.com/PARKINSONSDISEASEEDUCATION(15% off entire order when applying the code PARKINSONSDISEASEEDUCATION at checkout) Kizik Shoes: https://kizik.sjv.io/pdeducation Cure Hydration: https://lvnta.com/lv_XG06Rho8SSlXEq3qlV If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013 Medical Disclaimer All information, content, and material of this video is for informational purposes only and not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Affiliate disclaimer: Keep in mind that links used for recommended products may earn me a commission when you make purchases. However, this does not impact what products I recommend. If I recommend a specific product it is because it has been vetted by myself or based on personal use. #parkinson #parkinsonsawareness #parkinsonsdisease #parkinsons #prasinezumab #monoclonalantibodies #alphasynuclein

Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson's disease and outlines Phase II plans for the company's lead asset HER-096.

Listen below or click here for full show notes Star Trek’s Robert Picardo Pens Strong Message About Franchise’s History Ahead Of Starfleet Academy Robert Picardo Reminds Fans What STAR TREK Has Always Been as The Franchise Turns 60 — GeekTyrant Zoe Saldaña Becomes Highest-Grossing Actor of All Time With ‘Avatar 3’ Main Mission, Part 1 (with an appropriate sound effect) Star Trek: Starfleet AcademySeason 1, episode 1“Kids These Days”Written by Gaia VioloDirected by Alex Kurtzman Subspace Chatter Star Trek panoramas from the CD-ROM era – Boing Boing Exclusive: Christina Chong Talks “More Swings” For ‘Strange New Worlds' Season 4, “Bittersweet” Season 5 – TrekMovie.com Say Goodbye to Star Trek on Netflix Star Trek Fans Bought A Lot Of Props At Auctions In 2025, But I’m Shocked At The Most Expensive Get From The Next Generation Alex Kurtzman on Star Trek's Future — and Paramount's New Regime ‘Star Trek: Strange New Worlds’ Casts Sulu and Bones for Series Finale STAR TREK: STRANGE NEW WORLDS Series Finale Casts Thomas Jane as McCoy, Kai Murakami as Sulu – TrekCore.com Dr. McCoy and Mr. Sulu to Appear in Star Trek: Strange New Worlds Series Finale – IGN ‘Star Trek’ Legend Offered ‘Klingon School’ to 2026 Cast Warner Bros. Discovery Still Sounds Open to a Paramount Deal DOJ Reviewing Paramount’s Warner Bros. Discovery Bid Paramount Loses Bid to Fast Track WBD Disclosures on Netflix Deal Paramount Loses Bid to Fast Track WBD Disclosures on Netflix Deal In Vulcan, Alberta, Canada news… Town of Vulcan Recreation – Public Access Here are links to 144 additional stories.broken out by series, movies and other categories. CLASSIC TV SERIES (in order of premiere) Star Trek: The Original Series (1966 – 1969) [3 seasons] Star Trek: TOS S2 episodes to be thankful for on Turkey Day One Star Trek Actor Played Three Characters in the Original Series (After She Was Cut From The Pilot) Star Trek actress, 85, makes unexpected comments about co-star William Shatner | HELLO! Star Trek Used Kissing Noises To Create The Sound Of A Classic Monster Star Trek episode showed Trekkies just how funny the series could be 59 Years Later, This Star Trek: TOS Episode Remains the Scariest Hour in Sci-Fi TV History One Line From Star Trek: The Original Series Created A 58-Year Plot Hole The Star Trek spinoff Starfleet Academy is as much a school on-screen as it is off, according to co-star George Hawkins | Popverse Classic Star Trek Is Finding A New Audience Through YouTube Reaction Videos – TrekMovie.com One of Kirk’s Greatest ‘Star Trek’ Episodes Ever Is a Masterclass in 1 Thing the Sci-Fi Show Does Best One Star Trek Actor Couldn’t Do Spock’s Vulcan Salute Star Trek’s Tribbles Got Their Noise From A Very Unlikely Animal Star Trek: The Next Generation (1987 – 1994) [7 seasons] Star Trek: The Next Generation’s “Schisms” Is Still the Darkest Hour of Body Horror in Trek History Star Trek’s annoying TNG guests shouldn't stop fans from watching must-see Data episode “I can’t, they’re out of control”: Denise Crosby on Star Trek Director Getting Fed Up of TNG Cast Star Trek: TNG Is Superior Because It Respected One Rule The Original Series Constantly Broke All 7 Seasons of STAR TREK: TNG, Ranked 32.9M Streaming Hours Prove This ‘Star Trek' Spin-Off Aged Better Than Expected The Star Trek: The Next Generation Episode That Michael Dorn Considers The Worst Star Trek: The 7 Best Captain Picard Episodes Of All Time – ComicBook.com New Star Trek Show Finally Completes The Redemption Of The Next Generation’s Most Hated Character – ComicBook.com 6 Darkest Star Trek: The Next Generation Episodes, Ranked Star Trek: Deep Space Nine (1993 – 1999) [7 seasons] 28 Years Ago, Star Trek's Future Was Changed Forever in 2 Weeks Star Trek: Voyager (1995 – 2001) [7 seasons] Star Trek’s Controversial Janeway Episode Is the Most Problematic 46 Minutes in Sci-Fi History Star Trek: Voyager’s Best, Darkest Story Was Almost A Season-Long Adventure – ComicBook.com Star Trek: Enterprise (2001 – 2005) [4 seasons] The Worst ‘Star Trek' Episode Ever Pointlessly Killed Off a Beloved Character To “Create Conversation” STREAMING SERIES AND MOVIES (in order of premiere) Star trek: Prodigy (2021 – 2024) [2 seasons] Star Trek's Most Beloved Show Being Erased From Streaming In 2026, You Can’t Watch It | GIANT FREAKIN ROBOT Kate Mulgrew Reacts to ‘Star Trek: Prodigy’ Cancellation Star Trek: Strange New Worlds (2022 – present) [4th season yet to premier, 5th/final season finished filming] Star Trek: Strange New Worlds: Christina Chong Wraps Series Filming Star Trek: Strange New Worlds’ Christina Chong Shared A Post After Wrapping On The Final Season, And I’m Starting To Get Emotional | Cinemablend A Star Trek: Strange New Worlds Director Shared The Last Time The Cast Was On The Bridge, And I Have Two Big Questions | Cinemablend Star Trek actor can’t even find the words as Strange New Worlds wraps “Star Trek: Strange New Worlds” Cast & Crew Say Farewell STAR TREK: STRANGE NEW WORLDS Wraps Production; Cast Bids Farewell with Two Seasons Yet to Air – TrekCore.com Melissa Navia teases deeper trauma and untold backstory for Strange New Worlds pilot Erica Ortegas | Popverse Star Trek legacy villain could show up in Strange New Worlds finale (and this is how) Star Trek: Section 31 (streaming TV event) Star Trek: Section 31' Nominated For Image Award – TrekMovie.com Star Trek: Starfleet Academy [2026 – present] [renewed for second season] Paul Giamatti, Star Trek's Latest Villain, Just Proved His Trek Fandom to Us – IGN First Look: Wrestling Champion Becky Lynch On The ‘Star Trek: Starfleet Academy' Bridge – TrekMovie.com Star Trek’s Next Villain Is Channeling 4 of The Most Iconic Sci-Fi Bad Guys Of All Time – ComicBook.com Meet the Cadets of STAR TREK: STARFLEET ACADEMY in Video Spotlights, Plus Behind-the-Scenes Peeks at Production – TrekCore.com Set primarily on Earth, Star Trek: Starfleet Academy rethinks what a Star Trek series can be | Popverse Alex Kurtzman Explains Why Starfleet Academy Isn't Set Post-‘Picard,' Hints More Star Trek TV Is In Development – TrekMovie.com Star Trek Fans Clash Over Klingons as One Actor Responds – Parade Star Trek Star Hits Back At New Show’s Klingon Controversy – ComicBook.com 25 Years Later, New Star Trek Show Finally Fixes A Major Voyager Injustice – ComicBook.com Every Legacy Star Trek Character We Hope to See in Starfleet Academy ‘Most-Hated’ Character Honored in New ‘Starfleet Academy’ Clip – Parade Star Trek’s Next Series Is Breaking A Cardinal Rule Of Every Show So Far – ComicBook.com Star Trek: Starfleet Academy’s Karim Diane Knows His Klingon Character Is Different, But Explains Why It’s Not Uncommon | Cinemablend | Cinemablend Star Trek: Starfleet Academy — Season 1 review: ‘compelling’ Starfleet Academy Will Revive an Age-Old Star Trek Conundrum | Den of Geek ‘Star Trek: Starfleet Academy’: Paul Giamatti and Holly Hunter on beaming into the storied sci-fi franchise (interview) | Space Star Trek: Starfleet Academy – A Love Letter To Deep Space Nine In Episode 5 See New STAR TREK: STARFLEET ACADEMY Photos from This Week's Two-Episode Premiere, “Kids These Days” and “Beta Test” – TrekCore.com New Star Trek Spinoff Has an Unexpected Alien: Romulus Connection (Exclusive) Holly Hunter Says ‘Star Trek’ Role Is like ‘Winning the Lottery' Star Trek’s New Spinoff Officially Explores a Canon-Accurate Detail About Klingon Healers (Exclusive) Star Trek Confirmed The Return of a One Off Villain to Live-Action – ComicBook.com PREVIEW: Star Trek: Starfleet Academy Series Premiere – Trek Central Paul Giamatti On Villain in Big Fat Liar, Star Trek Starfleet Academy Holly Hunter & Paul Giamatti on ‘Star Trek: Starfleet Academy,’ Villains & Federation Legacy – YouTube Star Trek: The Burn profoundly affects Starfleet Academy Star Trek: Starfleet Academy's American Museum of Natural History premiere – downthetubes.net Star Trek: Starfleet Academy Review: Star Trek Meets College Drama in This Fun but Frustrating Series – TV Guide Star Trek: Starfleet Academy – Boldly Going Nowhere, But So Very Youthfully — Original Cin Star Trek: Starfleet Academy Review: A Playful New Spinoff Star Trek Starfleet Academy Review, Season 1 On Paramount Plus TV Review: What grade does STAR TREK: STARFLEET ACADEMY deserve? Starfleet Academy review: Star Trek kicks off 60th anniversary by connecting its past and future Star Trek: Starfleet Academy review – The kids are alright ‘Starfleet Academy’ Is a Solid Successor to the ‘Star Trek’ Legacy Early Review: ‘Starfleet Academy' Season 1 Deftly Balances Strong Characters, Star Trek Lore, And Different Tones – TrekMovie.com Star Trek: Starfleet Academy Brings Historic Firsts For The Franchise Star Trek is placing new show Starfleet Academy in an uncertain future to make it more meaningful for new fans today | Popverse ‘Star Trek: Starfleet Academy’ Brings Back What Fans Have Been Missing Star Trek Starfleet Academy TV Review: An introduction to the next generation of the franchise Star Trek Is About To Ruin Your Favorite Voyager Character Paul Giamatti Ranks His Favorite Star Trek Shows and Talks Star Trek: Starfleet Academy – YouTube Star Trek actor provides BTS tour of Starfleet Academy Exclusive: ‘Starfleet Academy' Showrunners Talk Easter Eggs, DS9 “Love Letter,” And Keeping Star Trek Alive – TrekMovie.com Exclusive: Robert Picardo And Gina Yashere On Ad Libbing & Season 2 Of ‘Star Trek: Starfleet Academy' – TrekMovie.com unannounced “Captain Janeway” series Star Trek: Kate Mulgrew on Janeway Spinoff Series Becoming a Reality unannounced “Resort Planet” series [currently in early development] “Star Trek” Comedy Series Update – Dark Horizons Trek series that never were, for one reason or another, [such as “Phase II”] 19 Lost ‘Star Trek’ Episodes From the Unproduced ‘Phase II’ Series | Woman’s World THEATRICAL MOTION PICTURES (in order of premiere) Star Trek: The Motion Picture (1979) William Shatner Said Star Trek: The Motion Picture’s Uniforms Threatened His ‘Ability To Procreate’ Star Trek II: The Wrath of Khan (1982) The Star Trek Actor Who Spoiled Spock’s Death Before Wrath Of Khan Even Began Shooting Star Trek VI: The Undiscovered Country (1989) 20 Things You Never Knew About Star Trek VI: The Undiscovered Country – video Dailymotion OTHER MEDIAStar Trek books, audio books Star Trek: Khan: Beyer Discusses Starfleet Academy, Canon Flexibility Star Trek collectibles Review — Fanhome's New USS Archer and USS Harlan Expand the STAR TREK Starship Collection – TrekCore.com EXO-6 Reveals New STAR TREK: STRANGE NEW WORLDS Captains Chair Replica with Authentic Lights and Sounds – TrekCore.com Star Trek DVDs Star Trek: SNW season 3 warp-speeds beyond digital (epic SteelBook on the horizon) Star Trek video games/board games Embracer sell Neverwinter and Star Trek Online devs Cryptic, allowing them to gather their party and boldly go where Saber went before | Rock Paper Shotgun Embracer Group sells publisher Arc Games and Star Trek Online developer Cryptic Studios, but once again clings on to the publishing rights for Remnant 2 | PC Gamer ICv2: New ‘Star Trek: Into the Unknown’ Release Features Cardassians and Klingons A Look Into ‘Star Trek: Star Realms – Borg: Invasion Expansion' Destination Board Game: Star Trek: The Next Generation– Master Replicas Master Replicas Unveils Three Star Trek XL Desk Mats Inspired by Iconic Bridge Stations – GameSpace.com “Star Trek: Voyager – Across the Unknown” Release Date & Switch 2 Confirmed; Watch New Gameplay Video – TrekMovie.com Star Trek Comics/graphic novels/magazines See Janeway Fight To Escape The Clutches Of Species 8472 In Preview Of ‘Star Trek: Voyager: Homecoming' #3 – TrekMovie.com The Resurrected Captain Kirk Takes Command in Star Trek: The Last Starship #3 – IGN The Wild STAR TREK: TNG ’80s Comic Had a Space Santa – Nerdist Star Trek Can’t Let Captain Kirk Go, And It’s Become A Problem Star Trek Celebrates 60th Anniversary with Webtoon Expansion in 2026 IDW Preview: Star Trek: Strange New Worlds: Seeds Of Salvation #5 | Comic Book Club In Review: Star Trek: Voyager—Homecoming #4 – Between A Rock and A Hard Place See Spock Befriend A Giant Space Squid In ‘Star Trek: Strange New Worlds: The Seeds of Salvation' #5 Preview – TrekMovie.com MISCELLANEOUS Franchise-wide/Miscellaneous 12 Philosophical Star Trek Episodes That Will Leave You Thinking It's Hard To Be Excited About ‘Starfleet Academy' When the Star Trek Franchise Is Struggling Netflix Says Goodbye to All Remaining Star Trek Titles From TOS to Strange New Worlds: How Long Will It Reasonably Take To Complete All Star Trek Episodes – Your Complete 2026 Guide A Brief History of Klingon-Federation Conflict 10 Best Holodeck Episodes In Star Trek, Ranked The life and legacy of Dr. Soong, the creator of Star Trek’s DataWhat To Expect From Star Trek In 2026: A Franchise At A Crossroads – TrekMovie.com Star Trek 2025: The Biggest News And Surprises Of The Year 10 Star Trek Episodes That Predicted The Future Star Trek’s Renaissance During Stranger Things’ 9-Year Run The Star Trek Movie Timeline, Explained Star Trek’s most fascinating moments of 2025 ranked worst to first ‘To boldly go where no-one has gone before’ – opinion – Western People 12 Strongest Star Trek Characters, Ranked By Power 10 Greatest Star Trek Moments In 2025 Star Trek’s best Captain Christopher Pike actors ranked Star Trek: Everything We NOW Know About The 25th Century – YouTube Star Trek Showrunner Accidentally Admits How Boomers Saved The Franchise | GIANT FREAKIN ROBOT Star Trek: 10 Times Captains Lost Control – video Dailymotion 10 Biggest Reveals In Star Trek Novels – video Dailymotion 10 Deleted Star Trek Scenes That Would Have Changed Everything Star Trek Franchise Head Alex Kurtzman Gave Us An Update On His Contract And How He Feels About His Future | Cinemablend Paramount+ Holds ‘Star Trek: Starfleet Academy' World Premiere Event – Media Play News STAR TREK: STARFLEET ACADEMY Starts Soft Before Hitting Warp Speed (Review) – Nerdist STAR TREK: STARFLEET ACADEMY's First Class Has a Promising Start — Our Spoiler-Free Review – TrekCore.com Star Trek’s Allegory-First Storytelling Rule is Fumbled by Most Franchises 5 Star Trek Characters That Were Nerfed Over Time Trekkies, Michael Westmore’s documentary trailer looks out of this world UPDATE: Star Trek NOT Eligible For New Emmy Legacy Award… Due To A Technicality – TrekMovie.com Hear Me Out: I Think Hallmark Should Make A Holiday Movie For Star Trek Fans | Cinemablend What Is To Be Done About Star Trek? | Comic Book Club Actor Watch Jeri Ryan’s Favorite Star Trek Episode Is A Classic Original Series Adventure Tig Notaro: ‘Star Trek: Starfleet Academy’ shows ‘same Tig, different galaxy’ | Out.com ‘Star Trek' Icon, 94, Announces Nostalgic Event — and Fans Are Thrilled Star Trek’s Michael Dorn Questioned The Direction Of One Klingon Design William Shatner Connects ‘Star Trek,’ ‘Twilight Zone’ and Wizard of Oz (Exclusive) | Woman’s World How Rebecca Romijn Became a ‘Star Trek' Legend on ‘Strange New Worlds’ | Woman’s World Main Mission, Part 2 (with an appropriate sound effect) Star Trek: Starfleet AcademySeason 1, episode 2“Beta Test”Written by Noga Landau & Jane MaggsDirected by Alex Kurtzman End Of Show It’s about time to refill the dilithium chamber and get on out of here. Find Clinton at Comedy4Cast Find Chuck and Kreg at Technorama Podcast If you liked the show, please be sure to tell a friend about it. And subscribe, so you’ll never miss an episode. We’d love to hear from you. Follow us on BlueSky (@thetopicistrek), visit our Facebook page or call us at 816-TREKKER, that’s (816) 873-5537 Don’t put on the red shirt!

Tinnitus isn't just a ringing in your ears — it can interfere with memory, mood, and sleep, affecting your overall well-being when left unmanaged A Phase II clinical trial found that low-intensity sound therapy (LINTS) can reduce tinnitus symptoms without blocking out real-world sounds, helping the brain tune out the ringing naturally Sound therapy works by helping your brain reclassify tinnitus as background noise, reducing its emotional and cognitive impact over time For best results, work with a professional — sound therapy is most effective when guided by a trained audiologist Supporting your body with antioxidant-rich foods, magnesium, deep sleep, and a low-stress lifestyle can also reduce tinnitus intensity and help protect your hearing

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Col. (ret.) Dr. Michael Milshtein, former head of the Department for Palestinian Affairs in Israel's Military Intelligence Directorate. They discuss the current status of the Gaza ceasefire deal, the contrasting realities on the ground in the Hamas-controlled red zone and the Israeli-controlled green zone, prospects for the U.S.-led Phase II of the deal, the upcoming meeting between Prime Minister Netanyahu and President Trump, fear of escalation in Lebanon, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

Today Pastor Stan explains how Phase II of the Gaza War COULD be the rise of the Third Beast. 00:00 Intro 01:27 Gang of Eight 05:50 Third Beast 14:31 Fourth Beast 15:05 Mark of the Beast

Today Pastor Stan explains how Phase II of the Gaza War COULD be the rise of the Third Beast. 00:00 Intro 01:27 Gang of Eight 05:50 Third Beast 14:31 Fourth Beast 15:05 Mark of the Beast

Today Pastor Stan explains how Phase II of the Gaza War COULD be the rise of the Third Beast. 00:00 Intro 01:27 Gang of Eight 05:50 Third Beast 14:31 Fourth Beast 15:05 Mark of the Beast

The US Senate Commerce Committee has voted to advance the nomination of Jared Isaacman to lead NASA. The Soyuz MS-27 crew has returned to Earth. Muon Space has been awarded a $1.9 million Small Business Innovation Research (SBIR) Direct to Phase II contract by SpaceWERX, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Dr. Michelle Hailey, Director of Global Affairs at Solamed Solutions. You can connect with Michelle on LinkedIn, and learn more about Solamed on their website. Selected Reading US Senate Committee votes to advance NASA nominee Jared Isaacman- Reuters NASA Astronaut Jonny Kim, Crewmates Return from Space Station Muon Space Secures Direct to Phase II Award Supporting Space Development Agency's Missile Warning and Tracking Mission Space Infrastructure Startup Mantis Space Selects Albuquerque for Headquarters and Manufacturing Hub Balerion Space Ventures Announces Strategic Investments in Three Companies Building the Infrastructure for America's Next Industrial Revolution In First, Wheelchair User Set To Go To Space - Disability Scoop Blue Origin Announces Crew for New Shepard's 37th Mission Share your feedback. What do you think about T-Minus Space Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

THIS VOYAGE, MARK A. ALTMAN (Pandora, The Librarians, 50 Year Mission), DAREN DOCHTERMAN (associate producer, STAR TREK: THE MOTION PICTURE) & ASHLEY E. MILLER (writer, Thor, X-Men: First Class) celebrate the 46th anniversary of STAR TREK: THE MOTION PICTURE as we are joined by associate producer JON POVILL, Epsilon 9 casualty MICHELE BILLY POVILL, publicist EDDIE EGAN, The Walking Dead showrunner and creative director SCOTT GIMPLE and Alien Boy himself, BILLY VAN ZADNT, whose been with the podcast every minute of her refitting. This is how we definite unwarranted! Join the Treksperts and special guests as we trace the development of Phase II's "In Thy Image" into the epic motion picture released December 7, 1979.**DON'T MISS THE TREKSPERTS AT GALAXYCON COLUMBUS 12/5 - 12/7 FOR MORE INFORMATION, GO TO GALAXYCON.COM ****TREKSPERTS+ SUBSCRIBERS NOW GET COMMERCIAL FREE EPISODES ONE WEEK EARLY! SUBSCRIBE TODAY AT TREKSPERTSPLUS.COM****Join us on our new INGLORIOUS TREKSPERTS DISCORD Channel at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/7kgmJSExeh⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rate and follow us on social media at:Blue Sky: @inglorioustrekspertsTwitter/X:@inglorioustrekFacebook:facebook.com/inglorioustrekspertsInstagram/Threads: @inglorioustrekspertsLearn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook and at @inglorioustreksperts on Instagram and Blue Sky. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed."Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times

Mining Stock Daily discusses the recent surge in the silver market and its impact on Argenta Silver, led by CEO Joaquin Marias. The discussion covers the company's new discovery at the Andrea Exploration Target, data-driven exploration strategies, and insights into the El Quevar South area. Marias emphasizes the importance of systematic exploration and the imminent results from their drilling program, highlighting the potential for significant silver and other mineral discoveries.

Kiran Patankar is the recently appointed CEO of Maple Gold Mines and he joined MSD to close out our coverage of the DGM in Frankfurt. Kiran shares some insights on renewing exploration activities at the Douay Gold project and the Joutel Gold Project. He talks about bringing new institutions and investors into the story to re-emerge the projects into the forefront of the investment community. Since the interview, the company did announce a 30,000m Phase II drill program.

Our good friends, Mike and JT from Brew Crime, join us for November's unsolved crossover. Today, JT tells us about a terrifying six-year murder spree (1990-1996) targeted at least thirteen vulnerable elderly women in Richmond's West End, creating widespread panic. The case was officially pinned on one killer, but the narrative quickly fell apart: the series was split by a two-year hiatus and featured a pronounced shift from the stabbing homicides of six Black women to the homicides of seven White women. The case was hastily "closed" for the Phase II victims through the highly disputed confession of a diagnosed schizophrenic with zero forensic links to the crime scenes, leaving the initial wave of brutal stabbings completely unresolved. The official resolution is rooted in systemic failure and alleged racial bias, ensuring the actual killer, or killers, walked free. Source for the Episode Associated Press. (1996, April 25). Pattern Sought in Richmond Killings. The Roanoke Times. https://scholar.lib.vt.edu/VA-news/ROA-Times/issues/1996/rt9604/960425/04250042.htm Cases Solved Using Forensic Genetic Genealogy: How DNA Profiles Crack Cold Cases. (n.d.). Genomelink. Retrieved November 3, 2025, from https://genomelink.io/blog/cases-solved-using-forensic-genetic-genealogy-how-dna-profiles-crack-cold-cases Leslie Burchart. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Leslie_Burchart Perpetrator typologies and behavioral patterns in strangulation homicides: A Smallest Space Analysis. (n.d.). PMC. Retrieved November 3, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12046104 The Golden Years Murders. (n.d.). In Wikipedia. Retrieved November 3, 2025, from https://en.wikipedia.org/wiki/Golden_Years_Murders https://richmondstandard.com/richmond/2025/02/26/richmond-city-council-honors-black-nine-guardians-of-justice/  Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on the Mark Levin Show, On Monday's Mark Levin Show, 7 million old hippies turned out in the Democrat-Marxist-Islamist No Kings mini-parades on Saturday? Well, 330 million Americans did not. The tea party movements had massive rallies, and it wasn't just one day. How is this President a king? He's working through the courts when he's blocked on improving America. For example, in a victory for America the 9th Circuit court ruled that the National Guard can be deployed in Portland. Also, Democrats turned a continuing resolution into a government shutdown blackmail threat to reverse provisions of the big, beautiful bill. Later, Marxist-Islamist Zohran Mamdani is pro-terrorism - from his associations with Imam Siraj Wahaj, his support for Hamas, his calls to globalize the Intifada, and his ties to the Qatar royal family. If people in NYC vote for Mamdani, they are voting for somebody who embraces terrorists, terrorist organizations, and hence, by implication, terrorism. Mamdani is no moderate, he's a grave threat to the people in New York City. Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy, and massive government spending to control the people. Later, Zohran Mamdani got his butt kicked at the NYC debate. He's a sloganeer, which is typical of Marxists, but he won't be substantive at all. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture China is now in talks again with the US, their plan has failed. Big Antimony refinery is being setup in Alaska, Trump is countering China every step of the way. Bessent warns the longer the shutdown goes it could hurt the economy, this is what the [CB] are trying to do. Investments are pouring into the US. Trump now has the [DS] where he wants them. They called in facist/Hitler and it has failed, he ushered in peace around the world and now when he has peace with Ukraine and Russia they will have a very difficult time pushing these names. The FBI has dismantled the largest human trafficking network. Trump is letting the people know that Phase II of the plan is now on track. Obama is struggling he looks defeated, by the time this is over he will try to escape to Kenya and the D party will cease to exist.   Economy (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/KobeissiLetter/status/1977907063893225928 New: Alaska Scores Big on Antimony Refinery  Antimony (Sb on the periodic table) is a strategic mineral with many applications. Shooters will recognize it, as it is frequently allied with lead to make a harder, more durable alloy for cast bullets. We should note that lead-antimony alloys have many other uses, from lead-acid batteries to sailboat keels. Antimony is used in other alloys as well, such as antifriction alloys, electric cable sheathing, and type metals for printing presses, which apparently are not completely extinct yet. It's also used in flame retardants, and - this is key - in semiconductors. It's also has applications in pharmaceuticals.  a key strategic mineral. Alaska has antimony. Now, in Alaska, a company called Nova Minerals, with a grant from the War Department, has a contract to build an antimony refinery at Port MacKenzie, west of Anchorage, to process ore from the Estelle gold mine in the West Susitna Mineral District. With Pentagon backing and a goal to begin delivering Alaska-sourced antimony into U.S. supply chains by 2027, Nova Minerals Ltd. has secured a 42.8-acre site at Port MacKenzie west of Anchorage for a refinery that would process antimony concentrates from its Estelle project and other sources."This is a defining moment for Nova Minerals and for U.S. critical mineral independence," Nova Minerals CEO Christopher Gerteisen said upon securing land use permits for the industrial site about four miles from a deepwater port in Southcentral Alaska.The refinery, to be developed by Nova subsidiary Alaska Range Resources (ARR), is part of a strategy to leverage the very high-grade antimony mineralization found on the company's Estelle project about 100 miles west of Port MacKenzie to establish a domestic supply of this metalloid critical to a wide range of military and commercial applications. Antimony is also found in Idaho and Montana. But a majority of antimony production comes from countries that are not particularly friendly to the United States: China, Russia, and Tajikistan, which, between them, account for almost 80 percent of global supply. Source: redstate.com Johnson Warns Current Government Shutdown Could Be Longest Ever House Speaker Mike Johnson (R-La.) said on Oct.

Send us a textAaron takes the mic solo and unloads on pipeline myths, training excuses, and bad packet habits. Forget the rumor mill—he explains why the Air Force keeps tweaking Special Warfare selection, why “pipeline optimization” isn't a conspiracy, and why faster runners are always the ones who graduate. He drags combat controllers over pistol skills, laughs about swim cap questions, and gives the blunt truth: stop wasting time and train specifically for what actually matters. It's snarky, savage, and brutally useful—classic Aaron, unfiltered.⏱️ Timestamps00:00 – Intro chaos and tech fail shoutout 02:05 – Pipeline rumors: water vs land 04:15 – Why change is constant in selection 08:55 – Pipeline optimization explained (no more wasted time) 11:05 – The real mission: why operators exist 15:40 – Selling the new pipeline in one sentence 17:50 – The Zulu Course: common skills, common pain 19:25 – Combat controller pistol roast 21:40 – What you should actually train for 23:55 – Why fast runners always win 28:40 – Pull-up standards and the Pose Fitness app 33:05 – Grip strength is king 35:20 – Swim efficiency and wall push-offs 39:50 – Stowe Phase I vs Phase II: packet perfection 44:30 – What Phase II really feels like 46:45 – Officers, packets, and dumb mistakes 49:05 – Who actually camps more: PJ, CCT, or SR? 55:35 – Underwaters in OCPs: why it sucks and how to prep 57:55 – Could the Air Force run its own schools? Nope